Home LiteratureArticle Details
PMID: 18275276 Published · ppublish English Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy.

The Journal of infectious diseases ·Vol. 197 ·No. 4 ·2008-02-15 ·Pages 563-71

Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, Baker B, Trocha A, Rosenberg R, Mackey E, Ueda P, Lu Z, Cohen D, Wrin T, Petropoulos CJ, Rosenberg ES, Walker BD

Abstract

Spontaneous control of human immunodeficiency virus (HIV) infection has been documented in a minority of HIV-infected individuals. The mechanisms behind this outcome remain largely unknown, and a better understanding of them will likely influence future vaccine strategies. HIV-specific T cell and antibody responses as well as host genetics were examined in untreated HIV-infected patients who maintain comparatively low plasma HIV RNA levels (hereafter, controllers), including those with levels of < 50 RNA copies/mL (elite controllers, n = 64), those with levels of 50-2000 copies/mL (viremic controllers, n = 60); we also examined HIV-specific T cell and antibody responses as well as host genetics for patients with levels of >10,000 copies/mL (chronic progressors, n = 30). CD8+ T cells from both controller groups preferentially target Gag over other proteins in the context of diverse HLA class I alleles, whereas responses are more broadly distributed in persons with progressive infection. Elite controllers represent a distinct group of individuals who have significantly more CD4 and CD8 T cells that secrete interferon-gamma and interleukin-2 and lower levels of HIV-neutralizing antibodies. Individual responses were quite heterogeneous, and none of the parameters evaluated was uniquely associated with the ability to control viremia. Elite controllers are a distinct group, even when compared to persons with low level viremia, but they exhibit marked genetic and immunologic heterogeneity. Even low-level viremia among HIV controllers was associated with measurable T cell dysfunction, which has implications for current prophylactic vaccine strategies.

MeSH Terms
Adult Aged CD8-Positive T-Lymphocytes/virology Cohort Studies Female Gene Products, gag/immunology HIV Infections/genetics,immunology HIV Long-Term Survivors HIV-1/immunology Humans Interferon-gamma/metabolism Interleukin-2/metabolism Male Middle Aged RNA, Viral Viral Load Viremia/genetics,immunology
Chemicals
Gene Products, gag Interleukin-2 RNA, Viral Interferon-gamma
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Pereyra Florencia
Partners AIDS Research Center, Massachusetts General Hospital, Boston, MA 02129, USA.
Addo Marylyn M
Kaufmann Daniel E
Liu Yang
Miura Toshiyuki
Rathod Almas
Baker Brett
Trocha Alicja
Rosenberg Rachel
Mackey Elizabeth
Ueda Peggy
Lu Zhigang
Cohen Daniel
Wrin Terri
Petropoulos Christos J
Rosenberg Eric S
Walker Bruce D
Article Info
Journal
The Journal of infectious diseases
Abbr.
J Infect Dis
ISSN
0022-1899
Published
2008-02-15
Pages
563-71
Language
English
Region
United States
NLM ID
0413675
Subset
IM
Grants
NHLBI NIH HHS · R01 HL092565 · United States
Howard Hughes Medical Institute · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com